Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: 25% of 3 seats
2
Feb 11, 2011 12:10PM
2
Feb 11, 2011 12:15PM
4
Feb 11, 2011 12:19PM

Rule 14a-11 also "dictates" the minimum market cap on a specfic date for shareholder nominations to be eligible for inclusion in the proxy.

As such, shareholders won't be able to circumvent it, in my very humble opinion, but any attempt to do so will obviously be a further drain on resources.

.

.

.

Be well

Share
New Message
Please login to post a reply